Wednesday, 22 Jan 2020

You are here

IL-17 Inhibitors In Non-Radiographic Axial SpA

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

We get to see new secukinumab (Late breaking abstract 21) 16 week data of their 555 patient trial with loading & no loading of 150mg of secukinumab versus placebo (1:1:1). Inclusion criteria are very important in this disease, as previous trials have been substantially affected by inclusion criteria, think poor response of adalimumab in ABILITY-1. Included patients had to meet the ASAS criteria and have an abnormal CRP or MRI. The primary endpoint was ASAS40 in TNF naïve patients at 16 weeks. Importantly 89-90% of patients were TNF inhibitor naïve and they had had their back pain for greater than 8 years. At week 16 42% of secukinumab patients met the primary endpoint versus 29% in the placebo group. Safety was consistent with previous secukinumab trials. 

We also get to see the ixekizumab (Plenary Session III, abstract 2729) 52 week data. Again, patients had to meet the ASAS criteria and also have an abnormal CRP or MRI and have an inadequate response to NSAIDs. Patients had had greater than 10 years of symptoms and a mean of 3-4 years since diagnosis. Patients were randomised (1:1:1) to placebo, 80mg every 2 weeks or 80mg every 4 weeks. The primary endpoint was ASAS40 at week 16 and week 52. At 16 weeks in the ITT population ASAS40 was 20%:34%:41% in placebo:Q4W:Q2W, and then at week 52 the ITT population ASAS40 was 14%:29%:32% in placebo:Q4W:Q2W.

It is very clear that the devil is in the detail when thinking about nr-axSpA and treatment response and the details that are important are CRP and MRI positivity, disease duration and previous biologic use. In nr-axSpA we have seen trials that have patients with short disease duration, a high proportion of positive CRP and MRI (or both even) and minimal previous biologic use have shown the best response. Therefore, comparisons between trials of different agents is much more challenging to try to get an idea of comparable efficacy. The take home is that anti-IL17 agents are effective in this condition but picking your patients carefully is likely to see a greater proportion responding favourably.

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.